Gain Therapeutics Inc. (GANX)
2.13
0.05 (2.40%)
At close: Jan 15, 2025, 3:59 PM
2.13
0.00%
After-hours Jan 15, 2025, 04:09 PM EST
Company Description
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding.
It focuses on rare genetic diseases and neurological disorders.
The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease.
It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases.
The company was founded in 2017 and is based in Bethesda, Maryland.
Gain Therapeutics Inc.
| Country | United States |
| IPO Date | Mar 19, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Gene Mack M.B.A. |
Contact Details
Address: 4800 Montgomery Lane Bethesda, Maryland United States | |
| Website | https://www.gaintherapeutics.com |
Stock Details
| Ticker Symbol | GANX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001819411 |
| CUSIP Number | 36269B105 |
| ISIN Number | US36269B1052 |
| Employer ID | 85-1726310 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gene Mack M.B.A. | Chief Financial Officer & Interim Chief Executive Officer |
| Dr. Joanne Taylor Ph.D. | Senior Vice President of Research |
| Dr. Jonas Hannestad M.D., Ph.D. | Chief Medical Officer |
| Dr. Khalid Islam Ph.D. | Executive Chairman |
| Dr. Terenzio Ignoni Pharm.D. | Senior Vice President of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 07, 2025 | 4 | Filing |
| Jan 07, 2025 | 8-K | Current Report |
| Dec 23, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |
| Oct 21, 2024 | 8-K | Current Report |
| Oct 08, 2024 | 8-K | Current Report |
| Sep 19, 2024 | S-8 | Filing |
| Sep 06, 2024 | 424B5 | Filing |
| Sep 06, 2024 | 8-K | Current Report |